← Back to all trials
Available
NCT05028166
Individual Patient Compassionate Use of Mirdametinib
Conditions: Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases
Sex: All
Ages: 2 Years – N/A
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Location: Please Contact U.S. Medical Information Billerica Massachusetts
Summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Eligibility Criteria
Inclusion Criteria:
* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
* Patient does not qualify to participate in an ongoing clinical trial.
Source: ClinicalTrials.gov (NCT05028166). StuddyBuddy aggregates publicly available trial information.
